Literature DB >> 11738361

The muscle-specific marker desmin is expressed in a proportion of human dermal fibroblasts after their exposure to galectin-1.

K Goldring1, G E Jones, C A Sewry, D J Watt.   

Abstract

We have previously shown that galectin-1 is a factor capable of converting mouse dermal fibroblasts to the myogenic lineage [Cell Transplant 2000;9:519]. Here, we report that human dermal fibroblasts are also capable of expressing the myogenic marker, desmin, when grown in muscle-cell-conditioned media. Furthermore, the human foetal skin cells also express this marker when grown in the presence of galectin-1. These results highlight the importance of galectin-1 in the conversion of both human and murine skin cells to a myogenic lineage. Thus galectin-1 could be an important tool for use in autologous cell therapies for the treatment of human muscular dystrophies.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11738361     DOI: 10.1016/s0960-8966(01)00280-2

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  4 in total

Review 1.  The involvement of galectin-1 in skeletal muscle determination, differentiation and regeneration.

Authors:  Diana J Watt; Gareth E Jones; Kirstin Goldring
Journal:  Glycoconj J       Date:  2002       Impact factor: 2.916

2.  Harnessing the therapeutic potential of myogenic stem cells.

Authors:  Jason D White; Miranda D Grounds
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

3.  Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy.

Authors:  Pam M Van Ry; Ryan D Wuebbles; Megan Key; Dean J Burkin
Journal:  Mol Ther       Date:  2015-06-08       Impact factor: 11.454

4.  Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1.

Authors:  Daniel G Cerri; Lílian C Rodrigues; Sean R Stowell; Daniela D Araujo; Mariana C Coelho; Sibere R Oliveira; João C S Bizario; Richard D Cummings; Marcelo Dias-Baruffi; Maria Cristina R Costa
Journal:  Glycobiology       Date:  2008-08-22       Impact factor: 4.313

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.